A Phase III, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Moderate-To-Severe Thyroid Eye Disease
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: ROCHE FARMA, SA
- Phase: III
- Execution start: 15/11/2023
- End of execution: 30/12/2025
- IP: SANTIAGO ORTIZ PEREZ